WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström’s Macroglobulinemia
Open Access
- 8 July 2026
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Abstract
WNK2 is a known tumor suppressor in a set of solid tumors, including glioblastoma multiforme and pancreatic ductal adenocarcinoma. WNK2 functions are largely unknown beyond the kinase domain (KD)-dependent inhibition of ERK1/2 signaling. Waldenström’s Macroglobulinemia (WM) is an indolent, yet incurable, B cell lymphoma characterized by highly recurrent MYD88 (MYD88MUT) and CXCR4 (CXCR4MUT) mutations that trigger sustained NF-κB and ERK1/2 signaling. Although not expressed in healthy B cells, WNK2 is a top dysregulated gene in MYD88MUT WM. To study WNK2 regulation and signaling, we performed multi-omics analyses, including bulk and PacBio Iso-Seq RNA-Seq and methylome, in 264 untreated WM and functional studies in cell lines and primary WM cells. Aberrant expression of WNK2 emerged as a near universal feature of early-stage WM and a hallmark of plasma cell-like MYD88MUT WM. We identified novel isoforms that carried a shared aberrant splicing event, either contained or lacked the KD and were highly expressed by the tumor cells, unlike the canonical full-length isoforms. Functionally, WNK2/S-NK1, the most expressed of the KD-lacking isoforms in WM, triggered a pro-inflammatory cascade that activated ERK1/2 and NF-κB signaling. We observed a similar, cancer-specific upregulation of WNK2 in a set of solid tumors, including the highly aggressive cholangiocarcinoma. Our findings reveal an undocumented oncogenic function for WNK2 driven by novel, cancer-specific isoforms and provide a framework for its further investigation as a determinant of disease progression in MYD88MUT WM and a novel therapeutic target in hematological and solid tumor oncology.Keywords
This publication has 49 references indexed in Scilit:
- Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activityBlood Cancer Journal, 2024
- RNA splicing dysregulation and the hallmarks of cancerNature Reviews Cancer, 2023
- Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrenceJournal of Hepatology, 2019
- Salmon provides fast and bias-aware quantification of transcript expressionNature Methods, 2017
- Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signalingLeukemia, 2016
- Intrinsically disordered proteins in cellular signalling and regulationNature Reviews Molecular Cell Biology, 2014
- The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s MacroglobulinemiaLeukemia, 2014
- Classification of Intrinsically Disordered Regions and ProteinsChemical Reviews, 2014
- Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma developmentOncogene, 2013
- WNK2 modulates MEK1 activity through the Rho GTPase pathwayCellular Signalling, 2008